TG Therapeutics Inc Expected to Earn FY2020 Earnings of ($1.71) Per Share (TGTX)

Share on StockTwits

TG Therapeutics Inc (NASDAQ:TGTX) – Equities research analysts at SunTrust Banks dropped their FY2020 earnings per share estimates for TG Therapeutics in a research note issued on Monday, April 1st. SunTrust Banks analyst P. Lawson now forecasts that the biopharmaceutical company will post earnings of ($1.71) per share for the year, down from their prior forecast of ($1.69). SunTrust Banks also issued estimates for TG Therapeutics’ FY2021 earnings at ($1.59) EPS and FY2022 earnings at ($0.40) EPS.

TGTX has been the subject of a number of other reports. BidaskClub downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 17th. Jefferies Financial Group restated a “buy” rating and issued a $8.00 price target on shares of TG Therapeutics in a research report on Wednesday, February 6th. B. Riley started coverage on TG Therapeutics in a research report on Tuesday, January 8th. They issued a “buy” rating and a $10.00 price target for the company. Zacks Investment Research downgraded TG Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 30th. Finally, ValuEngine downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, February 28th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $14.07.

NASDAQ TGTX opened at $8.32 on Thursday. The company has a market cap of $727.52 million, a PE ratio of -4.36 and a beta of 2.31. TG Therapeutics has a one year low of $3.32 and a one year high of $16.00.

Institutional investors have recently made changes to their positions in the company. Deutsche Bank AG boosted its holdings in TG Therapeutics by 72.2% in the fourth quarter. Deutsche Bank AG now owns 824,164 shares of the biopharmaceutical company’s stock worth $3,378,000 after acquiring an additional 345,477 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of TG Therapeutics by 10.3% during the fourth quarter. Geode Capital Management LLC now owns 755,205 shares of the biopharmaceutical company’s stock worth $3,096,000 after purchasing an additional 70,398 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of TG Therapeutics by 10.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 71,312 shares of the biopharmaceutical company’s stock worth $292,000 after purchasing an additional 6,812 shares during the period. Great Point Partners LLC lifted its holdings in shares of TG Therapeutics by 53.8% during the fourth quarter. Great Point Partners LLC now owns 3,000,000 shares of the biopharmaceutical company’s stock worth $12,300,000 after purchasing an additional 1,050,000 shares during the period. Finally, Opaleye Management Inc. lifted its holdings in shares of TG Therapeutics by 57.1% during the fourth quarter. Opaleye Management Inc. now owns 550,000 shares of the biopharmaceutical company’s stock worth $2,255,000 after purchasing an additional 200,000 shares during the period. Hedge funds and other institutional investors own 55.59% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.

Featured Article: Understanding Price to Earnings Ratio (PE)

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

FintruX Network  Trading 26.5% Lower  Over Last 7 Days
FintruX Network Trading 26.5% Lower Over Last 7 Days
Panhandle Oil and Gas Inc.  Given $23.50 Average Target Price by Brokerages
Panhandle Oil and Gas Inc. Given $23.50 Average Target Price by Brokerages
Propy Tops 24 Hour Trading Volume of $2.36 Million
Propy Tops 24 Hour Trading Volume of $2.36 Million
Zacks: Dawson Geophysical Co  Given Average Rating of “Buy” by Brokerages
Zacks: Dawson Geophysical Co Given Average Rating of “Buy” by Brokerages
Brokerages Anticipate Jefferies Financial Group Inc  to Announce $0.24 Earnings Per Share
Brokerages Anticipate Jefferies Financial Group Inc to Announce $0.24 Earnings Per Share
Bismuth  Hits 1-Day Trading Volume of $903.00
Bismuth Hits 1-Day Trading Volume of $903.00


© 2006-2019 Ticker Report